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Diagnostic, management and nursing challenges of less common 
dementias: Parkinsonian dementias and Huntington’s disease 
Abstract 
Background: Although most cases of dementia are caused by Alzheimer’s disease or vascular 
dementia, around 10-15% of cases are due to other disorders, including dementias with 
Parkinsonian features, Huntington’s disease, frontotemporal dementia, human 
immunodeficiency virus (HIV), and alcohol.  
Aims: These less common dementias are important as they may have differing clinical 
features and require different approaches to diagnosis and management. This paper seeks 
to provide relevant information for nurses about symptoms, diagnosis and management of 
some of the less common dementias. 
Methods: This is one of two connected papers, and provides a clinical overview of 
Parkinsonian dementias and Huntington’s disease. It provides a narrative, rather than 
systematic, review of the literature. 
Findings: Parkinsonian dementias comprise Parkinson’s disease dementia, dementia with 
Lewy bodies and so-called Parkinson’s-plus syndromes (multi-system atrophy, progressive 
supranuclear palsy, and corticobasal degeneration). Huntington’s disease is an inherited 
neuropsychiatric condition. Each has a distinctive clinical picture, with combinations of 
cognitive, neuropsychiatric and neurological symptoms but approaches to treatment and 
care are essentially supportive.   
Conclusions: Nurses have an essential role in supporting people with dementia, as well their 
families and carers, throughout the course of dementia from diagnosis to end of life care. 
They are often best placed and have the necessary skills to create appropriate care plans 







Over 537,000 people in the UK have a dementia diagnosis (Alzheimer's Research UK, 2020). 
The most common causes of dementia are Alzheimer’s disease (AD) (accounting for two-
thirds of all cases) and vascular dementia, but there are also many lesser-known causes, 
which altogether perhaps account for 10-15% of all cases. Therefore, although these 
disorders are ‘less common’, some of them are far from rare. The less common forms of 
dementia differ in aetiology, incidence, clinical features, age of onset, prognosis and ability 
to treat (Dening and Babu Sandilyan, 2015a; 2015b). These forms of dementia may often 
cause diagnostic and management difficulties.  
Less common dementias often present at younger ages, with wide-ranging signs and symptoms. They 
may be more likely to be part of an underlying neurological syndrome. Prompt diagnosis enables 
careful and considered care planning to occur at an early stage.  
The diagnosis of dementia mostly remains a clinical process. Investigations, such as neuroimaging, are 
important in terms of establishing the cause of the dementia, and there is currently much interest in 
validating biomarkers, especially in AD (Olsson et al, 2016). The heavy emphasis on memory 
impairment in clinical criteria lends itself more towards a diagnosis of Alzheimer’s dementia and is less 
help in diagnosing less common causes (Dening and Babu Sandilyan, 2015a; 2015b).  
This paper is the first of two about some of the important and less common dementias, in which we 
consider their diagnosis and management. The authors will also discuss the provision of support to 
patients and families, including the contribution of nursing. Part one includes the various types of 
dementia with Parkinsonian features and Huntington’s disease; Part 2 will discuss frontotemporal 
dementia, HIV dementia and alcoholic dementia.  
Dementias with Parkinsonian features 
This is a mixed group of disorders (see Table 1), including Lewy body spectrum disorders 
(encompassing Parkinson’s disease (PD), Parkinson’s disease dementia (PDD), and Lewy body 
dementia (DLB)), and the so-called Parkinson-plus syndromes, which are other forms of dementia 
with Parkinsonian features, including corticobasal degeneration (CBD), multi-system atrophy (MSA) 
and progressive supranuclear palsy (PSP). The Lewy body disorders and MSA are 
synucleinopathies—that is, they are characterised by accumulation of the protein α-synuclein in the 
central nervous system. In contrast, PSP and CBD are characterised by accumulation of insoluble tau 





Table 1: Summary of the key features of dementias with Parkinsonian features 
Synucleinopathies Pathology Features  
Parkinson’s 
disease dementia 
Lewy bodies, cholinergic 
deficits 
 
Likely: Early motor symptoms, early visuospatial and executive dysfunction, 
retrieval memory impairment, REM sleep behaviour disorder, visual hallucinations 
Less likely: Early cognitive decline 
Lewy body 
dementia 
Lewy bodies in the 
cortex, brainstem and 
limbic regions, dopamine 
and acetylcholine 
abnormalities 
Likely: Early falls, retrieval memory problems, early and fluctuating cognitive 
impairments in attention, visuospatial and executive function, antipsychotic 
sensitivity, hyposmia, REM sleep behaviour disorder, early visual hallucinations. 




causing glial and myelin 
dysfunction and 
neurodegeneration. 
Likely: Early autonomic symptoms, cerebellar signs, parkinsonism, restless legs, 
speech impairment, laryngeal stridor, relatively preserved cognitive function. 
Less likely: Hyposmia 




Accumulation of tau in 
neurofibrillary tangles 
with degeneration of 
nigral and subcortical 
areas 
Likely: Early falls, postural instability, gait problems, vertical supranuclear gaze 
palsy, pseudobulbar palsy, early and severe cognitive impairment (frontal) 
Less likely: REM sleep behaviour disorder, olfactory problems 
Corticobasal 
degeneration 
Degeneration of the 
cerebral cortex and 
deeper brain regions. 
Likely: Limb rigidity, bradykinesia, postural instability, alien limb, visuospatial 
deficits, apraxia, dysarthria and aphasia, episodic memory reasonably preserved 
Less likely: Early memory impairment, typical Parkinsonian resting tremor 
 
Parkinson’s disease dementia 
PD is a well-known disease of motor function due to dopaminergic neuron loss in the substantia nigra. 
PD is also associated with mild cognitive impairment (MCI), and with a risk of dementia that is nearly 
6 times that of age matched counterparts (Poewe et al, 2008). Estimates of the progression of MCI to 
dementia in PD are highly variable (from 5–100%) and seem to depend on heterogeneity in the study 
design. This degree of variation seems unhelpful, and further research is needed (Hu et al, 2014; Pigott 
et al, 2015).  
Prevalence of cognitive impairment increases with illness duration, older age of onset of PD, 
movement disorder severity, poor cognitive baseline, and history of REM sleep behaviour disorder 






PDD appears distinct from AD, both in cognitive profile and neuropathology. The pathological hallmark 
of PD, Lewy bodies, progresses in a predictable way, and the cortical spread may be linked to the 
severity of cognitive impairment (Braak et al, 2005). Cholinergic deficits appear to play a role in 
cognitive dysfunction. 
Clinical features 
Early visuospatial and executive dysfunction are more common in PDD, in contrast to the prominent 
early short-term memory loss and language deficits seen in AD. Interestingly, impaired driving ability 
in mild to moderate PD has been associated with these early deficits, rather than with motor 
symptoms (Uc et al, 2007). When they do occur, memory impairments involve retrieval difficulties 
assisted with cues.  
RSBD can occur years before the onset of PD or DLB. Visual hallucinations can occur in cognitively 
intact patients, but their presence (often of people/animals) increases the likelihood of developing a 
dementia (Fénelon et al, 2000). Personality changes, such as loss of emotional control, outbursts of 
anger and obsessive behaviours, may occur.  
Diagnosis 
Distinguishing PDD from DLB is difficult; this is largely done on the basis of the temporal relationship 
of the motor and cognitive symptoms. Diagnosis requires the development of a dementia syndrome 
in the context of established PD. However, accurate diagnosis cannot be made without a detailed 
history. The cognitive decline in DLB may be more rapid, with earlier onset of delusions and 
hallucinations. The motor symptoms may be of greater severity in PDD, and tremor may be more 
common (Galasko, 2017).  
Dementia with Lewy bodies 
DLB has characteristic Lewy bodies (abnormal deposits of alpha-synuclein in the cortex, brainstem and 
limbic regions of the brain) affecting neurotransmitter systems (particularly dopamine and 
acetylcholine), which give rise to clinical features.  
DLB can overlap with AD, with a third to half of those with diagnosed AD revealing co-existing Lewy 
body pathology on post-mortem (Outeiro et al, 2019). 
Clinical features 
In contrast to PDD, the dementia either precedes or occurs simultaneously with the motor symptoms. 
Its onset may be abrupt, with rapid progression. Falls may be an early presenting symptom. Memory 
can be considerably preserved compared with AD but, when present, demonstrates retrieval 





cognition (in contrast to PDD) and vivid visual hallucinations which may predate parkinsonism 
(Jellinger, 2018). Indeed, cognitive fluctuations and visual hallucinations form part of the increasingly-
recognised syndrome of mild cognitive impairment with Lewy bodies (Donaghy et al, 2018). 
Early impairments in attention, executive and visuospatial functioning often cause patients or others 
to notice a decline in work function or driving competency before more severe deficits appear. 
Parkinsonism can be as severe as PD, although it is usually milder, bilateral and symmetrical. People 
with DLB are often highly sensitive to antipsychotic medication. Hyposmia may be an early feature 
and can help to distinguish DLB from AD (Beach et al, 2020).  
RSBD, including disturbed sleep wake cycle, nightmares, confusion and acting out dreams, may 
predate the diagnosis of DLB by several years. Daytime somnolence, long naps and episodes of staring 
and disorganised speech correlate better with DLB than AD (Ferman et al, 2004). Confusingly, patients 
may have autonomic dysfunction resembling that seen in MSA, although of a lesser severity 
(Thaisetthawatkul et al, 2004). 
Diagnosis 
Probable DLB requires the presence of two symptoms of fluctuating cognition, visual hallucinations, 
extrapyramidal signs and RSBD. Specificity at autopsy is around 85%, which means that scoring 
positively on the criteria means the patient is fairly likely to have DLB (Outeiro et al, 2019).  
Management of PDD and DLB 
There is no cure for PDD or DLB. Management of the Lewy body dementias (DLB and PDD) has been 
recently reviewed by Taylor et al (2020). There are now clinical trials and meta-analyses that provide 
evidence to guide treatment of cognitive, neuropsychiatric and motor symptoms. The cholinesterase 
inhibitors donepezil and rivastigmine are recommended for the treatment of the cognitive disorder of 
DLB (National Institute for Health and Care Excellence (NICE), 2018), and rivastigmine has been shown 
to be of some benefit in PDD (Rolinski et al, 2012). 
The management of neuropsychiatric symptoms can be challenging. Psychotic symptoms can be 
attributable to the dementia or side effects of antiparkinsonian medication. Treating the debilitating 
movement disorder without worsening psychotic symptoms and cognition is a fine balance. Visual 
hallucinations are particularly distressing when they occur, and medication may be required. If 
antipsychotics are to be used, quetiapine or clozapine may be preferred, although the risks of vascular 
events and death remain. Medications, such as tricyclic antidepressants, benzodiazepines, 
anticholinergics and dopamine agonists, can impact on cognition, and patients should be managed on 





Non-pharmacological approaches (treating reversible causes, drug toxicity and environmental factors) 
are generally recommended as the first line of approach to behavioural and psychological symptoms, 
especially given the importance of these in other dementias and the lack of robust pharmacological 
interventions (Connors et al, 2018). Alternative approaches involving cognitive training and exercise 
may help improve cognition in this population (PDD), but further research is needed (Szeto and Lewis, 
2016).  
The often lengthy duration of these neurodegenerative conditions provide opportunities for nurses 
to have meaningful input into complex disease management, which not only means pharmacological 
management, but also having difficult conversations about realistic disease progression and the more 
practical aspects of planning for the future (Lennard, 2018).  
Parkinson-plus syndromes 
Parkinson-plus syndromes are a group of neurodegenerative atypical Parkinsonian disorders.  
Multi-system atrophy  
MSA affects the central and sympathetic nervous system and is both a synucleinopathy and 
tauopathy. MSA appears to be a spectrum of three disorders: cerebellar MSA (MSA-C), parkinsonian 
MSA (MSA-P) and olivopontocerebellar atrophy (OPCA). 
The exact cause is unknown, but abnormal proteins may cause glial and myelin dysfunction and 
neurodegeneration (Jellinger, 2014). The degree of cognitive dysfunction may correlate with cortical 
involvement (Bak et al, 2005). It is rapidly progressive, and patients may be bedbound within 5-8 years 
(Tada et al, 2007). 
Clinical presentation  
All subtypes have early autonomic symptoms; urogenital symptoms usually occur first. Others include 
orthostatic hypotension and erectile dysfunction. Urinary dysfunction also occurs in PD, but its 
occurrence in MSA is much earlier (within less than 2 years in one study) (Bloch et al, 2010). 
Predictably, MSA-C has predominant cerebellar signs (ataxia, eye movement disorders, ataxic 
dysarthria), whereas MSA-P has predominant Parkinsonism. Olivopontocerebellar atrophy affects 
balance, coordination and speech. 
RSBD is common, presenting in up to two-thirds of patients (Plazzi et al, 1997). Restless legs and 
daytime somnolence affects up to 30% of patients (Moreno-López et al, 2011). A reasonably specific 
feature for MSA is laryngeal stridor (Cortelli et al, 2019), initially occurring during sleep with daytime 
occurrence with disease progression. There is an association with sudden death (Silber and Levine, 





Cognitive function is often well preserved, but up to 20% of MSA patients may develop dementia 
(Brown et al, 2010).   
Parkinsonian symptoms may occur before autonomic symptoms, which causes diagnostic difficulty, 
since MSA-P may appear identical to PD in the early stages. Autonomic failure can also occur in DLB 
and PD (Palermo et al, 2020). In DLB, the degree of cognitive impairment can be similar to that seen 
in MSA; therefore, DLB accompanied by autonomic impairment can be difficult to distinguish from 
MSA (Koga et al, 2015).  
Diagnosis 
Probable diagnosis of MSA requires autonomic dysfunction (urinary incontinence or erectile 
dysfunction) or orthostatic hypotension and either parkinsonism poorly responsive to levodopa or 
cerebellar syndrome.  
If possible, an accurate and early diagnosis is valuable, due to the rapid progression of the disease and 
the huge difference in life expectancy between PD and MSA. However, a definite diagnosis of MSA 
can only be made following post-mortem examination. The accuracy of clinical diagnosis varies 
between 60–78% (Koga et al, 2015; Miki et al, 2019). Neuroimaging is of some help, but a retrospective 
study comparing diagnosis in life with autopsy results showed 38% of MSA patients had normal 
neuroimaging (MRI) (Koga et al, 2015). The appearance of the pons on MRI is sometimes said to 
resemble a hot cross bun, but this sign is uncommon and nonspecific (Koga et al, 2015). 
MSA patients can show an initial, but unsustained, response to levodopa (Parati et al, 1993), and they 
are more likely than PD patients to suffer side effects (particularly dyskinesias and orthostatic 
hypotension). 
Progressive supranuclear palsy  
There are several variant phenotypes of PSP. The most common type is known as Richardson’s 
syndrome. Other phenotypes consist of the same presentation combined with other clinical features, 
such as frontal or cerebellar signs. 
PSP may be caused by a complex interplay of genetic and environmental factors (Litvan, 2004). The 
condition results in accumulation of tau proteins in neurofibrillary tangles, with degeneration of the 
nigral and subcortical areas. 
Clinical presentation 
Patients tend to present with postural instability, early falls (usually backwards) and gait problems 






PSP is associated with the development of a vertical supranuclear gaze palsy (people can move their 
eyes sideways but not up and down) and a pseudobulbar palsy. There may be a distinctive ‘astonished’ 
facial expression due to facial dystonia and oculomotor abnormalities (Litvan, 2004).  
Cognitive impairment (often early and severe) is common and tends to involve frontal lobe 
dysfunction. Patients show difficulty processing information, executive dysfunction and reduced 
verbal fluency (Litvan, 2004). They may have speech and language impairments. Behavioural 
problems, such as anger, emotional lability and disinhibition, may be present.  
Insomnia can be an issue, but RSBD is uncommon (Boeve et al, 2003). Olfaction is preserved. These 
traits and the cognitive impairment may help differentiate between PSP, PD and MSA. 
The decline in functioning is usually rapid, resulting in a need for full care within 3-4 years.  
Diagnosis 
As there are multiple variants of PSP, the clinical presentation can vary quite substantially, often 
leading to a late diagnosis. Diagnosis should be considered with rapidly progressive Parkinsonian signs, 
early falls, oculomotor deficits and poor levodopa response.  
Diagnosis is clinical; neuroimaging can be supportive but is not diagnostic. It may show generalised 
and brainstem atrophy. An appearance known as the hummingbird sign may be seen on MRI, which 
is due to midbrain atrophy with preservation of the pons (Page and Gaillard, 2020).  
There are standardised diagnostic criteria that identify possible, probable and definite PSP, and a 
definitive diagnosis relies on post-mortem identification of neurofibrillary tangles in the basal ganglia 
and brainstem (Hauw et al, 1994). ‘Possible’ PSP diagnosis requires either vertical supranuclear gaze 
palsy, or a combination of slowed vertical saccades and postural instability, causing falls in the first 
year. Probable diagnosis requires all three of these features.  
Corticobasal degeneration  
In CBD, parts of the cerebral cortex and deeper brain regions, such as the basal ganglia, degenerate. 
Diagnosis antemortem remains low (25–56% of cases) (Armstrong et al, 2013). Prognosis is variable, 
but the median survival in two studies was 5.5 and 7.9 years (Wenning et al, 1998; Murray et al, 2007). 
Clinical presentation 
Varying phenotypes cause varying symptomatology. Cortical and extrapyramidal symptoms may start 
unilaterally (usually affecting one limb) and spread bilaterally. Cognitive or behavioural changes may 
precede motor symptoms. Behaviours tend to reflect frontal involvement, with compulsive behaviour, 





Extrapyramidal signs include appendicular rigidity (which can be severe), less severe axial rigidity and 
limb dystonia (Wenning et al, 1998). Limb rigidity, bradykinesia or clumsy limb and postural instability 
are the most common presenting motor signs. The gait may resemble PD or be more wide-based. 
Tremor is less common in PSP than in PD, occurring in up to about 40% of cases, though it is often mild 
or intermittent, so may not even be observed (Fujioka et al, 2016). 
Cognitive features include visuospatial impairment, apraxia (ideomotor and ideational), changes in 
speech (including dysarthria and aphasia). Episodic memory may be reasonably preserved, and 
memory difficulties are due to retrieval problems (Pillon et al, 1995). 
With progression, there is eventual involvement of upper and lower extremities. The ‘alien limb’ 
phenomenon (patient feels their limb does not belong to them, has a mind of its own and is not under 
voluntary control) occurs in 30–50% of cases (Hanna and Doody, 2000). There may be some 
oculomotor dysfunction, with slow saccadic pursuit movements (Stover and Watts, 2001). 
Diagnosis 
Neuroimaging may show asymmetric cortical atrophy and, in particular, fronto-parietal atrophy. The 
EEG may be abnormal with disease progression. 
Definitive diagnosis is by postmortem examination showing asymmetric fronto-parietal atrophy, 
degeneration and depigmentation of the substantia nigra (Boeve et al, 1999). The cortex shows 
neuronal loss, achromatic swollen neurons and neurofibrillary tangles in a distribution similar to PSP. 
However, making the diagnosis in life remains complicated, due to the variable clinical features of the 
disease, which do not always correlate with the underlying neuropathology (Lee et al, 2011). One 
study found that only 35% of those diagnosed in life were diagnosed with CBD postmortem (Lee et al, 
2011). 
A diagnosis of probable CBD requires an asymmetric presentation and at least two signs of limb rigidity 
or akinesia, limb dystonia, limb myoclonus and one of orobuccal or limb apraxia, cortical sensory 
deficit or alien limb (Armstrong et al, 2013).  
Management of Parkinson-plus syndromes 
There is no curative or disease-modifying treatment for any of the syndromes, so management 
focuses on symptomatic treatment. They tend to respond poorly to dopaminergic drugs, although 
some cases may have temporary benefits, so a trial may be worthwhile. There may be troubling side 
effects, including visual hallucinations and dyskinesias. 
In CBD, tremor and myoclonus may respond to benzodiazepines, and baclofen may help with rigidity. 





The motor symptoms of MSA are difficult to treat, and there are no effective treatments for the 
cerebellar symptoms. Orthostatic hypotension can be treated with non-pharmacological measures, 
such as compression stockings or easing dietary salt restriction, or with medication, such as 
fludrocortisone.  
The evidence base is limited, and many findings are extrapolated from Parkinson’s disease studies; 
however, one recent systematic review highlights the importance of speech and language therapy 
(Tilley et al, 2016). Speech and language therapy, occupational therapy and physiotherapy can be 
useful in maintaining mobility for as long as possible. Swallowing difficulties may progress to such a 
stage that artificial feeding may be necessary. 
The important contributions of nursing are considered below in the Discussion section of this paper.  
Huntington’s disease  
Huntington’s disease (HD) is a genetic neurodegenerative disorder causing progressive movement, 
cognitive and neuropsychiatric symptoms, inherited in an autosomal dominant fashion; there is a 50% 
risk with one affected parent. The near perfect penetrance means that ‘all carriers eventually become 
patients’ (Alzheimer Europe, 2005). The mutation to the Huntington gene on chromosome 4 leads to 
an expansion of the CAG trinucleotide repeat. Successive generations often have an earlier age of 
onset, are associated with higher numbers of repeats, more rapid progression and a shorter life 
expectancy. 
Life expectancy is around 20 years from onset. The symptoms and progression of HD remain 
devastating to patients and their families. 
People living with HD may initially be able to live reasonably independently while experiencing 
relatively minor motor and cognitive deficits. With progression, this becomes less tenable as reliance 
on others due to cognitive and motor decline increases. The late stages may see patients bedbound. 
Clinical presentation 
HD is diagnosed by the presence of chorea, a family history and a positive genetic test. Predictive 
genetic testing is available before the presentation of clinical symptoms, and the decision to undergo 
testing, either before or after symptom presentation, is a personal one fraught with moral and ethical 
dilemmas. 
Motor symptoms change over the duration of the illness and are both hyper- and hypokinetic. 
Bradykinesia tends to occur early and increases throughout the duration of illness to akinetic rigidity 





to occur in the later stages (Burgunder et al, 2011). Eye movements, including the ability of the eyes 
to accurately jump between targets, may also be affected.  
Inevitably, at some point patients are likely to experience neuropsychiatric symptoms (agitation, 
irritability, dysphoria, anxiety, apathy, psychosis, sleep disorders, impulsivity), either due to side 
effects of medication, the inherent neurodegeneration in the brain or psychological consequences of 
adjusting to and living with a diagnosis of HD. Suicide rates are 4-6 times that of the general 
population, and suicidal ideation is elevated in HD carriers (20%) (Wetzel et al, 2011). 
Even early on, emotional recognition is impaired. Sufferers may have difficulties recognising their own 
actions and feelings, leading to family difficulties and challenging behaviours. They may exhibit 
impaired perception of time, spatial recognition and difficulty identifying smells. Often, they are 
unaware or in denial of their condition (anosognosia) (Wibawa et al, 2020). 
Cognitive changes include executive dysfunction, problems with memory retrieval and difficulties with 
concentration and attention (Ghosh and Tabrizi, 2018). Decision-making and multi-tasking may be 
difficult. Patients may struggle with planning and sequencing, causing difficulties at work and home. 
Subtle neurological and cognitive signs (e.g. minimal choreiform movements, problems with memory 
and attention, or even changes in personality like becoming less considerate), as well as neuroimaging 
changes, may occur many years prior to clinical symptoms (Aylward et al, 2004). 
Management 
Whilst HD dementia is incurable, there is some symptomatic treatment. Treatment can be difficult, 
due to the tendency of certain side effects to help one symptom and worsen another. That said, good 
management of symptoms and patient and carer education can delay institutionalisation and carer 
burnout. The importance of advance care planning cannot be emphasised enough. The ability to plan 
for the future, such as with an advance care plan or an advance decision to refuse invasive treatment, 
enhances an individual’s autonomy, and nurses are well placed to assist with this process. With the 
establishment of a good therapeutic relationship, nurses are able to share the patient’s journey, 
including ongoing discussion of hopes and wishes (Lennard, 2018). 
The inherited nature of HD presents its own challenges. It often presents in middle age or younger, 
thus causing different problems to those with the condition, family and carers compared to, for 
example, the challenges of late onset AD. It is estimated that, for each person with the HD gene, a 
further 20 people are affected, due either to the significant dependence on caregivers or the genetic 
effects of inheritance (Domaradzki, 2015). Given the mode of inheritance, the implications of testing, 





whole life trajectory can change in an instant: ’once the result of the test is disclosed, the individual 
and the family cannot live without the knowledge it brings’ (Andersson et al, 2016).  
Neuropsychiatric symptoms 
Cholinesterase inhibitors and memantine, which are used for AD, are ineffective in HD (Fernandez et 
al, 2000). 
An understanding of the underlying causes of challenging behaviour (such as difficulties 
communicating needs), pain, environmental factors, underlying medical and psychiatric conditions is 
important, and Table 2 shows some of the treatments used for frequently observed symptoms. 
Irritability is common and may be a combination of loss of impulse control, frustration with being 
unable to complete previously routine tasks, and unawareness. Expert consensus guidelines published 
in 2018 identify benzodiazepines, antidepressants and antipsychotic medications as potentially 
helpful (Anderson et al, 2018). Melatonin may aid sleep.  
Table 2: Medications often used in treatment of symptoms in Huntington’s disease 
Irritability 
SSRIs; antipsychotics; mood stabilising anti-
epileptics 
Acute agitation Benzodiazepines; antipsychotic medication 
Persistent agitation Antipsychotics; mood stabilising anti-epileptics 
Anxiety Antidepressants; antipsychotics 
Apathy 




Melatonin; hypnotics; sedating antidepressants; 
sedating antipsychotics 
 
Discussion: the nursing role 
Even in a brief account like this, it is apparent that these different dementia-causing disorders have 
their own distinct diagnostic, management and personal challenges. Unfortunately, apart from 
genetic testing in HD, there is no definitive diagnostic test; instead, accurate and timely diagnosis rests 
on a comprehensive clinical history and neurological examination. As several of these disorders are 





diseases, the diagnosis may not always be initially accurate. It may be that the correct diagnosis only 
emerges with time. Lewy body spectrum disorders and Parkinson-plus disorders may be initially 
misdiagnosed as PD, but unusual features, such as early falls, visual hallucinations, autonomic 
instability and oculomotor dysfunction, may indicate a rarer cause.  
Nurses play an important role at different stages of dementia. This includes post-diagnostic support, 
signposting patients and their families to sources of information and advice, and helping people to 
review their changed situations (with regard to employment, driving, social activities, and managing 
their financial affairs, for example). It may also include offering anxiety management or other forms 
of psychological support, such as mindfulness, to alleviate distress among people with dementia 
and/or their families. Alongside lasting powers of attorney, advance care planning is important, as are 
respite, care packages and hospices in the later stages, to aid families and carers (Thompson et al, 
2020). Nurses are often well-placed to act as care managers for the complex array of health and social 
care arrangements that may be needed for a person living with dementia and their family. 
Particularly in relation to the Parkinsonian dementias, nurses may be well-placed to detect the 
emergence of new or unexpected symptoms, since they are more likely to spend more time, over a 
longer period, with patients and families. This may be helpful in flagging the possibility of DLB in a 
person with supposed AD, or in helping to detect early symptoms that suggest a Parkinson-plus 
condition. Doing so may help point to interventions of treatments that are helpful or which may 
reduce the risk of harm—from overuse of antipsychotic medication in DLB, for example.  
Collectively, when it comes to these conditions, there are no curative or disease-modifying 
treatments, just symptomatic management. While timely diagnosis is not easy, these rarer causes of 
dementia should be considered. Specialist nurses are available for some. However, all nurses, 
(whether specialist Parkinson’s disease nurses, Huntington’s disease nurses, Admiral dementia nurses 
or generalist nurses) have a large part to play in providing appropriate, timely and joined-up care to 
both patients and those supporting them. With growing numbers of patients with dementia 
(particularly less common subtypes), generalist nurses may feel underqualified or out of their depth. 
Given the life-changing nature of a diagnosis of dementia and the positive impact that good nursing 
can have—from timely diagnosis NS support to patients and carers to the provision of appropriate 
information regarding future care planning to preventing avoidable emergency admissions—it is 
important that nurses are aware of how to acquire the necessary skills. Therefore, it is important that 
nursing education includes sufficient coverage of dementia and also that nurses have post-
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Key points 
Less common types of dementia cause 10-15% of all cases of dementia, and the most 
important are dementias with Parkinsonian features, Huntington’s disease, frontotemporal 
dementia, human immunodeficiency virus (HIV), Creutzfeldt-Jakob disease and other prion 
diseases, and alcohol. This paper discusses Parkinsonian dementias and Huntington’s 
disease. 
Parkinsonian dementias include Parkinson’s disease dementia (PDD), dementia with Lewy 
bodies (DLB), and Parkinson’s-plus syndromes such as multi-system atrophy, progressive 
supranuclear palsy and corticobasal degeneration. PDD and DLB appear to be on a spectrum 
as to whether the earliest features are motor or cognitive in nature. DLB has a distinct 
pattern that can enable it to be separated from Alzheimer’s disease, and it seems to have a 
more rapid course and worse outcomes. 
There are no cures for these disorders, so the emphasis in on supporting patients and their 
families, and in dealing with symptoms and other problems as they arise. Nurses are often 
well placed to develop and manage care plans that adapt along with the progressive nature 
of these conditions.  
 
CPD questions 
In your practice, have you seen patients with Parkinson’s disease, especially those who have 
had it for several years? Think about what their mental state was like, for example, mood, 
concentration, memory. You may have noticed that their condition fluctuated and that 
treating their symptoms became more difficult over time. 
Think about why it may be important to diagnose somebody as having dementia with Lewy 
bodies rather than having Alzheimer’s disease. What might you need to explain to them and 





Reflect on the problems that may arise from having rapid eye movement sleep behaviour 
disorder (RSBD). First think about what the patient may notice and then consider what it 
would be like to be trying to sleep in the same bed. 
Unless you work in a very specialised clinic, you may not see many people with disorders 
like progressive supranuclear palsy or corticobasal degeneration. So how would you prepare 
yourself to provide care for them if you find yourself looking after a patient with one of 
these conditions? How much knowledge do you think you would need? 
Consider the impact on a family if one of the adults is diagnosed with Huntington’s disease. 
How many people are likely to be at risk of having the condition? What are the issues about 








Alzheimer's Research UK. Diagnoses in the UK. 2020. 
www.dementiastatistics.org/statistics/diagnoses-in-the-uk/ (accessed 16 March 2021) 
Alzheimer Europe. Rare forms of dementia. 2005. 
https://ec.europa.eu/health/archive/ph_threats/non_com/docs/raredementias_en.pdf 
(accessed 16 March 2021) 
Anderson KE, Van Duijn E, Craufurd D et al. Clinical management of neuropsychiatric 
symptoms of Huntington disease: expert-based consensus guidelines on agitation, anxiety, 
apathy, psychosis and sleep disorders. J Huntingtons Dis. 2018;7(3):355-366. 
https://doi.org/10.3233/jhd-180293 
Andersson PL, Petersén Å, Graff C, Edberg AK. Ethical aspects of a predictive test for 
Huntington's disease: a long term perspective. Nurs Ethics. 2016;23(5):565-575. 
https://doi.org/10.1177/0969733015576356 
Armstrong MJ, Litvan I, Lang AE et al. Criteria for the diagnosis of corticobasal degeneration. 
Neurology. 2013;80(5):496-503. http://doi:10.1212/WNL.0b013e31827f0fd1 
Armstrong MJ, McFarland N. Recognizing and treating atypical Parkinson disorders. Handb 
Clin Neurol. 2019;167:301-320. http://doi:10.1016/b978-0-12-804766-8.00016-9 
Aylward EH, Sparks  F, Field KM. et al Onset and rate of striatal atrophy in preclinical 
Huntington disease. Neurology. 2004;63(1):66-72. 
http://doi:10.1212/01.wnl.0000132965.14653.d1 
Bak TH, Crawford LM, Hearn VC et al. Subcortical dementia revisited: similarities and 
differences in cognitive function between progressive supranuclear palsy (PSP), corticobasal 
degeneration (CBD) and multiple system atrophy (MSA). Neurocase. 2005;11(4):268-273. 
http://doi:10.1080/13554790590962997 
Beach TG, Adler CH, Zhang N et al. Severe hyposmia distinguishes neuropathologically 
confirmed dementia with Lewy bodies from Alzheimer's disease dementia. PLoS One. 
2020;15(4):e0231720. http://doi:10.1371/journal.pone.0231720 
Bloch F, Pichon B, Bonnet AM et al. Urodynamic analysis in multiple system atrophy: 
characterisation of detrusor-sphincter dyssynergia. J Neurol. 2010;257(12):1986-1991. 
http://doi:10.1007/s00415-010-5645-x 
Boeve BF, Maraganore DM, Parisi JE et al. Pathologic heterogeneity in clinically diagnosed 
corticobasal degeneration. Neurology. 1999;53(4):795-800. http://doi:10.1212/wnl.53.4.795 
Boeve BF, Silber MH, Parisi JE et al. Synucleinopathy pathology and REM sleep behavior 






Braak H, Rüb U, Jansen Steur EN et al. Cognitive status correlates with neuropathologic 
stage in Parkinson disease. Neurology. 2005;64(8):1404-1410. 
http://doi:10.1212/01.wnl.0000158422.41380.82 
Brown RG, Lacomblez L, Landwehrmeyer BG et al. Cognitive impairment in patients with 
multiple system atrophy and progressive supranuclear palsy. Brain. 2010;133(8):2382-2393. 
http://doi:10.1093/brain/awq158 
Burgunder JM, Guttman M, Perlman S et al. An international survey-based algorithm for the 
pharmacologic treatment of chorea in Huntington's disease. PLoS Curr. 2011;3:RRN1260. 
http://doi:10.1371/currents.RRN1260 
Connors MH, Quinto L, McKeith I et al. Non-pharmacological interventions for Lewy body 
dementia: a systematic review. Psychol Med. 2018;48(11):1749-1758. 
http://doi:10.1017/s0033291717003257 
Cortelli P, Calandra-Buonaura G, Benarroch EE et al. Stridor in multiple system atrophy: 
consensus statement on diagnosis, prognosis, and treatment. Neurology. 2019;93(14):630-
639. http://doi:10.1212/wnl.0000000000008208 
Dening T, Babu Sandilyan M. Medical treatment and management of patients with 
dementia. Nurs Stand. 2015;29(45):43-49. http://doi:10.7748/ns.29.45.43.e9424 
Dening T, Sandilyan MB. Dementia: definitions and types. Nurs Stand. 2015;29(37): 37-42. 
http://doi:10.7748/ns.29.37.37.e9405 
Domaradzki J. The impact of Huntington disease on family carers: a literature overview. 
Psychiatr Pol. 2015;49(5):931-944. http://doi:10.12740/pp/34496 
Donaghy PC, Taylor JP, O'Brien JT et al. Neuropsychiatric symptoms and cognitive profile in 
mild cognitive impairment with Lewy bodies. Psychol Med. 2018;48(14):2384-2390. 
http://doi:10.1017/s0033291717003956 
Fénelon G, Mahieux F, Huon R, and Ziégler M. Hallucinations in Parkinson's disease: 
prevalence, phenomenology and risk factors. Brain. 2000;123(4):733-745. 
http://doi:10.1093/brain/123.4.733 
Ferman TJ, Smith GE, Boeve BF et al. DLB fluctuations: specific features that reliably 
differentiate DLB from AD and normal aging. Neurology. 2004;62(2):181-187. 
http://doi:10.1212/wnl.62.2.181 
Fernandez HH, Friedman JH, Grace J, Beason-Hazen S. Donepezil for Huntington's disease. 
Movement Disorders. 2000;15(1):173-176. http://doi:10.1002/1531-
8257(200001)15:1<173::aid-mds1032>3.0.co;2-t 
Fujioka S, Algom AA, Murray ME, et al. Tremor in progressive supranuclear 






Galasko D.  Lewy body disorders. Neurol Clin. 2017;35(2):325-338. 
http://doi:10.1016/j.ncl.2017.01.004 
Geldmacher DS. Differential diagnosis of dementia syndromes. Clin Geriatr Med. 
2004;20(1):27-43. http://doi:10.1016/j.cger.2003.10.006 
Ghosh R, Tabrizi SJ. Clinical features of Huntington's disease. Adv Exp Med Biol. 
2018;1049:1-28. http://doi:10.1007/978-3-319-71779-1_1 
Hanna PA, Doody RS. Alien limb sign. Adv Neurol. 2000;82:135-145.  
Hauw JJ, Daniel SE, Dickson D et al. Preliminary NINDS neuropathologic criteria for Steele-
Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology. 
1994;44(11):2015-2019. http://doi:10.1212/wnl.44.11.2015 
Higher Education for Dementia Network (HEDN). A curriculum for UK dementia education. 
2015.  https://www.dementiauk.org/wp-content/uploads/2015/10/hedn_final-for-web-
with-hyperlinks.1.pdf (accessed 21 March 2021) 
Hu MT, Szewczyk-Królikowski K, Tomlinson P et al. Predictors of cognitive impairment in an 
early stage Parkinson's disease cohort. Mov Disord. 2014;29(3):351-359. 
http://doi:10.1002/mds.25748 
Jellinger KA. Neuropathology of multiple system atrophy: new thoughts about pathogenesis. 
Mov Disord. 2014;29(14):1720-1741. http://doi:10.1002/mds.26052 
Jellinger KA. Dementia with Lewy bodies and Parkinson's disease-dementia: current 
concepts and controversies. J Neural Transm (Vienna). 2018;125(4):615-650. 
http://doi:10.1007/s00702-017-1821-9 
Kikuchi A, Baba T, Hasegawa T. Differentiating Parkinson's disease from multiple system 
atrophy by [123I] meta-iodobenzylguanidine myocardial scintigraphy and olfactory test. 
Parkinsonism Relat Disord. 2011;17(9):698-700. http://doi:10.1016/j.parkreldis.2011.07.011 
Koga S, Aoki N, Uitti RJ et al. When DLB, PD, and PSP masquerade as MSA: an autopsy study 
of 134 patients. Neurology. 2015;85(5):404-412. 
http://doi:10.1212/wnl.0000000000001807 
Lee SE, Rabinovici GD, Mayo MC et al. Clinicopathological correlations in corticobasal 
degeneration. Ann Neurol. 2011;70(2):327-340. http://doi:10.1002/ana.22424 
Lennard C. Best interest versus advance decisions to refuse treatment in advance care 
planning for neurodegenerative illness. Br J Nurs. 2018;27(21):1261-1267. 
http://doi:10.12968/bjon.2018.27.21.1261 
Litvan I. Update on progressive supranuclear palsy. Curr Neurol Neurosci Rep. 
2004;4(4):296-302. http://doi:10.1007/s11910-004-0055-z 
Miki Y, Foti S C, Asi Y T et al. Improving diagnostic accuracy of multiple system atrophy: a 





Moreno-López C, Santamaría J, Salamero M. Excessive daytime sleepiness in multiple 
system atrophy (SLEEMSA study). Arch Neurol. 2011;68(2):223-230. 
http://doi:10.1001/archneurol.2010.359 
Mormont E, Laurier-Grymonprez L, Baisset-Mouly C., and Pasquier F.  The profile of memory 
disturbance in early Lewy body dementia differs from that in Alzheimer's disease (article in 
French). Rev Neurol (Paris). 2003;159(8-9):762-766.  
Murray R, Neumann M, Forman MS et al. Cognitive and motor assessment in autopsy-
proven corticobasal degeneration. Neurology. 2007;68(16):1274-1283. 
http://doi:10.1212/01.wnl.0000259519.78480.c3 
National Institute for Health and Care Excellence (NICE). Dementia: assessment, 
management and support for people living with dementia and their carers. 2018. 
https://www.nice.org.uk/guidance/ng97 (accessed 21 March 2021) 
Olsson B, Lautner R, Andreasson U et al. CSF and blood biomarkers for the diagnosis of 
Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673-
684. http://doi:10.1016/s1474-4422(16)00070-3 
Outeiro TF, Koss DJ, Erskine D et al. Dementia with Lewy bodies: an update and outlook. Mol 
Neurodegener. 2019;14(1):5. http://doi:10.1186/s13024-019-0306-8 
Page I, Gaillard F.  Descriptive neuroradiology: beyond the hummingbird. Pract Neurol. 
2020. http://doi:10.1136/practneurol-2020-002526 
Palermo G, Del Prete E, Bonuccelli U, Ceravolo R. Early autonomic and cognitive dysfunction 
in PD, DLB and MSA: blurring the boundaries between α-synucleinopathies. J Neurol. 
2020;267(12):3444-3456. http://doi:10.1007/s00415-020-09985-z 
Parati EA, Fetoni V, Geminiani et al.Response to L-DOPA in multiple system atrophy. Clin 
Neuropharmacol. 1993;16(2):139-144. http://doi:10.1097/00002826-199304000-00006 
Pigott K, Rick J, Xie SX et al. Longitudinal study of normal cognition in Parkinson disease. 
Neurology. 2015;85(15):1276-1282. http://doi:10.1212/wnl.0000000000002001 
Pillon B, Blin J, Vidailhet M et al. The neuropsychological pattern of corticobasal 
degeneration: comparison with progressive supranuclear palsy and Alzheimer's disease. 
Neurology. 1995;45(8):1477-1483. doi:10.1212/wnl.45.8.1477 
Plazzi G, Corsini R, Provini F et al. REM sleep behavior disorders in multiple system atrophy. 
Neurology. 1997;48(4):1094-1097. http://doi:10.1212/wnl.48.4.1094 
Poewe W, Gauthier S, Aarsland D et al. Diagnosis and management of Parkinson's disease 
dementia. Int J Clin Pract. 2008;62(10):1581-1587. http://doi:10.1111/j.1742-
1241.2008.01869.x 
Rolinski M, Fox C, Maidment I, McShane, R. Cholinesterase inhibitors for dementia with 





Cochrane Database Syst Rev. 2012; (3):Cd006504. 
http://doi:10.1002/14651858.CD006504.pub2 
Silber MH, Levine S. Stridor and death in multiple system atrophy. Mov Disord. 
2000;15(4):699-704. http://doi:10.1002/1531-8257(200007)15:4<699::aid-
mds1015>3.0.co;2-l 
Stover NP, Watts RL. Corticobasal degeneration. Semin Neurol. 2001;21(1):49-58. 
http://doi:10.1055/s-2001-13119 
Szeto JY, Lewis SJ.  Current treatment options for Alzheimer's disease and Parkinson's 
disease dementia. Curr Neuropharmacol. 2016;14(4):326-338. 
http://doi:10.2174/1570159x14666151208112754 
Tada M, Onodera, O, Tada M et al. Early development of autonomic dysfunction may predict 
poor prognosis in patients with multiple system atrophy. Arch Neurol. 2007;64(2):256-260. 
http://doi:10.1001/archneur.64.2.256 
Taylor JP, McKeith IG, Burn DJ et al.  New evidence on the management of Lewy body 
dementia. Lancet Neurol. 2020;19(2):157-169. http://doi:10.1016/s1474-4422(19)30153-x 
Thaisetthawatkul P, Boeve BF, Benarroch EE et al. Autonomic dysfunction in dementia with 
Lewy bodies. Neurology. 2004;62(10):1804-1809. 
http://doi:10.1212/01.wnl.0000125192.69777.6d 
Thompson G, Hack T, Rodger K et al. Clarifying the information and support needs of family 
caregivers of nursing home residents with advancing dementia. Dementia (London). 2020 
1471301220927617. http://doi:10.1177/1471301220927617 
Tilley E, McLoughlin J, Koblar SA et al. Effectiveness of allied health therapy in the 
symptomatic management of progressive supranuclear palsy: a systematic review. JBI 
Database System Rev Implement Rep. 2016;14(6):148-195. http://doi:10.11124/jbisrir-
2016-2002352 
Uc EY, Rizzo, M, Anderson SW et al. Impaired navigation in drivers with Parkinson's disease. 
Brain. 2007;130(Pt 9):2433-2440. http://doi:10.1093/brain/awm178 
Wenning GK, Litvan I, Jankovic J et al. Natural history and survival of 14 patients with 
corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg 
Psychiatry. 1998;64(2):184-189. http://doi:10.1136/jnnp.64.2.184 
Wetzel HH, Gehl CR, Dellefave-Castillo L et al. Suicidal ideation in Huntington disease: the 
role of comorbidity. Psychiatry Res. 2011;188(3):372-376. 
http://doi:10.1016/j.psychres.2011.05.006 
Wibawa P, Zombor R, Dragovic M et al. Anosognosia Is associated with greater caregiver 
burden and poorer executive function in Huntington disease. J Geriatr Psychiatry Neurol. 
2020;33(1):52-58. http://doi:10.1177/0891988719856697 
 
